02
Feb
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Alzheimer's, X - Inflammation
Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
29
Sep
2009
23
Jul
2009
15
Jun
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA
Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.
01
Feb
2009
19
Jan
2009
Posted in I - Series B, Q - 1Q09, R - MID WEST, X - Alzheimer's, X - CNS, XX - WI
Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.
12
Jan
2009
Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Alzheimer's, X - Neurology, X - Parkinson's, XX - CA
Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.
05
Dec
2008
01
Dec
2008
01
Dec
2008